GAMBARAN EFEK SAMPING PANDUAN STANDAR JANGKA PENDEK DAN PANJANG PADA TUBERKULOSIS RESISTEN OBAT
Annisa Nurfaujiah1, Ferdy Ferdian2, Basti Andriyoko3
1Program Studi Pendidikan Dokter, Fakultas Kedokteran, Universitas Padjadjaran
2Divisi Respirologi, Departemen Penyakit Dalam, Rumah Sakit Umum Hasan sadikin, Fakultas Kedokteran Universitas Padjadjaran, Bandung.
3Departemen Patologi Klinik, Rumah Sakit Umum Hasan sadikin, Fakultas Kedokteran Universitas Padjadjaran, Bandung

ABSTRACT

Drug resistant TB treatment requires more drugs, longer duration and more side effects. In 2020 WHO introduced an all-oral combination with a higher success rate but with additional side effect challenges. It is a descriptive observational study with a cross-sectional study design. The data used are medical records of patients aged over 18 years who have been declared complete treatment of TB-RO in January 2020 – June 2022 with an oral regimen of short-term and long-term treatment. Abnormal data results at the initial examination before starting treatment and incomplete or missing medical record data were not included in the study. The number of samples is determined by the total sampling method. The result from 69 patients who received short-term treatment combinations, nausea was the most common side effect (76.19%), followed by hyperuricemia (69.8%), vomit (55.56%), and QTc interval prolongation (44.44%). Out of 16 patients who received a combination of long-term treatment, the highest incidence was nausea (75%), arthralgia (62.5%) rash, itching, and headache (56.25%).The incidence of gastrointestinal disturbances, QTc prolongation, skin discoloration, hyperuricemia, hepatotoxicity, chest pain and tightness, and psychiatric disorders was higher in the short-term group. Meanwhile in the long-term regimen, tachycardia, itching and rash, arthralgia, visual and hearing impairment, neurological disorders, and neuropathy. Peripheral anemia and anemia were more common.
Keywords: Side Effects; Drug Resistant Tuberculosis; STR; LTR